Opthea Limited (NASDAQ:OPT – Free Report) – Stock analysts at HC Wainwright raised their FY2025 earnings per share estimates for Opthea in a report issued on Tuesday, September 3rd. HC Wainwright analyst M. Caufield now expects that the company will post earnings of ($0.25) per share for the year, up from their prior estimate of ($2.08). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Opthea’s current full-year earnings is ($2.03) per share. HC Wainwright also issued estimates for Opthea’s FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.03) EPS and FY2028 earnings at $0.19 EPS.
Opthea Price Performance
NASDAQ:OPT opened at $2.89 on Friday. Opthea has a 1 year low of $1.60 and a 1 year high of $4.40. The stock has a 50-day moving average price of $2.37 and a two-hundred day moving average price of $2.93.
Opthea Company Profile
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Read More
- Five stocks we like better than Opthea
- Learn Technical Analysis Skills to Master the Stock Market
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- Canadian Penny Stocks: Can They Make You Rich?
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.
